Literature DB >> 28049958

Treatment strategy of elderly rheumatoid arthritis.

Tsuyoshi Takeda1.   

Abstract

Since the general population is ageing, the number and the mean age of elderly patients of rheumatoid arthritis (RA) have increased. Elderly RA is classified into two clinical subsets, younger onset elderly RA (YORA) and elderly-onset RA (EORA). In the past literature, onset after 60 years of age is mainly adopted as the classical definition of EORA. Elderly-YORA patients, in addition to disease-modifying antirheumatic drugs, sometimes need analgestics, joint surgery and rehabilitation taking into account their bone destruction and their activities of daily living. Early phase EORA patients should be treated using the treat-to-target strategy, although low disease activity is the realistic goal due to their co-morbidities, patient factors and drug-related risks. Methotrexate (MTX) is the anchor drug in the treatment of EORA. It should be started at low dose (2-4 mg/day) and if tolerated, the dosage is carefully increased. In the case of renal dysfunction or dementia, and MTX is intolerable, biologics monotherapy could be a choice of treatment. Tapering of glucocorticoid, as far as possible, is needed because it is one of the risk factors of infection. Treatment of super-aged RA patients is a future agenda.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28049958     DOI: 10.2177/jsci.39.497

Source DB:  PubMed          Journal:  Nihon Rinsho Meneki Gakkai Kaishi        ISSN: 0911-4300


  3 in total

1.  Activity limitation and participation restriction in Osteoarthritis and Rheumatoid arthritis: findings based on the National Health and Nutritional Examination Survey.

Authors:  John Marwa Gikaro; Hao Xiong; Feng Lin
Journal:  BMC Musculoskelet Disord       Date:  2022-07-06       Impact factor: 2.562

2.  Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry.

Authors:  Sae Ochi; Koshiro Sonomoto; Shingo Nakayamada; Yoshiya Tanaka
Journal:  Arthritis Res Ther       Date:  2022-03-01       Impact factor: 5.156

3.  Fusion proteins of biologic agents in the treatment of rheumatoid arthritis (RA): A network meta-analysis.

Authors:  Mingcai Wu; Mengjun Tao; Quanhai Wang; Xiaohua Lu; Hui Yuan
Journal:  Medicine (Baltimore)       Date:  2021-06-18       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.